Evidence map›Paper›PMID 42435892›Full record

Trial reportJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2026

Transient ischemic dilation with

Sevan Letourneau-Shesaf, Yimin Chen, Mark Lemley, Giselle Ramirez, Paul Kavanagh, Aakash Shanbhag, Joanna X Liang, Christopher Buckley, Robert J H Miller, Daniel S Berman and 1 more

Abstract readMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sevan Letourneau-ShesafArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yimin ChenArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Mark LemleyArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Giselle RamirezArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Paul KavanaghArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Aakash ShanbhagArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Joanna X LiangArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Christopher BuckleyPharmaceutical Diagnostics, GE Healthcare, Buckinghamshire, United Kingdom.
Robert J H MillerDepartment of Cardiac Sciences, University of Calgary, Calgary Alberta, Canada.
Daniel S BermanArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Piotr SlomkaArtificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Piotr.slomka@csmc.edu.

Funding

Patient-specific Outcome Prediction from Cardiovascular Multimodality Imaging by Artificial IntelligenceR35HL161195 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Piotr J Slomka · 2022 to 2026
$5.0M
NHLBI NIH HHS R35 HL161195
6 · The paper itself

Abstract

backgroundTransient ischemic dilation (TID) of the left ventricule (LV) is a specific marker of extensive coronary artery disease (CAD). Normal limits for TID using

methodsWe performed a secondary analysis of the multicenter phase III flurpiridaz-301 trial, which included patients with suspected CAD who underwent rest-stress

resultsAmong 746 patients with evaluable PET, SPECT, and angiographic data, stress-specific TID reference thresholds (97.5th percentile) for

conclusionsThis study suggests stress-specific reference thresholds for TID using

Indexed as

Coronary Artery DiseaseMyocardial IschemiaPositron-Emission TomographyPyridazinesRadiopharmaceuticalsAgedCoronary AngiographyFemaleHumansMaleMiddle AgedMyocardial Perfusion ImagingReference ValuesTomography, Emission-Computed, Single-PhotonBMS 747158-02PyridazinesRadiopharmaceuticalsCoronary artery diseaseIschemiaPETTID

Identifiers

PMID42435892
PMCPMC13489666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.